Venrock Adviser, LLC

Name: Venrock Adviser, LLC: Form 13F holdings for the quarter ended 2026-06-30
Creator: Listed

An institutional investment manager in NEW YORK, NY. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1615982.

Share this page

Link

Story card, 1080 × 1920

Reported value$3.30bn
Positions33

Holdings: 33 positions

The filing on sec.gov

As filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.

Venrock Adviser, LLC, holdings
Issuer	Class	CUSIP	Reported value$m	Weight	Shares	Change on the quarter before
Apogee Therapeutics Inc	COM	03770N101	1,127	34.2%	8,493,321	Unchanged
Oruka Therapeutics IncORKA	COM	687604108	395	12.0%	4,148,428	Unchanged
Erasca IncERAS	COM	29479A108	328	9.9%	17,891,812	Added+1,509,000
Spyre Therapeutics IncSYRE	COM NEW	00773J202	265	8.0%	2,985,448	Reduced−700,000
Dianthus Therapeutics IncDNTH	COM	252828108	115	3.5%	1,180,000	Unchanged
Ocular Therapeutix IncOCUL	COM	67576A100	102	3.1%	10,346,926	Unchanged
Damora Therapeutics Inc	COM NEW	36322Q206	93.7	2.8%	3,603,595	Unchanged
Savara IncSVRA	COM	805111101	90.8	2.8%	14,745,943	Added+1,005,568
Jade Biosciences IncJBIO	COM NEW	008064206	71.6	2.2%	3,220,364	Unchanged
Cogent Biosciences IncCOGT	COM	19240Q201	63.6	1.9%	1,642,166	Reduced−357,834
Viridian Therapeutics IncVRDN	COM	92790C104	59.8	1.8%	3,257,917	Reduced−624,792
VOR Biopharma IncVOR	COM NEW	929033207	56.0	1.7%	3,041,719	Unchanged
Dyne Therapeutics IncDYN	COM	26818M108	48.3	1.5%	2,173,913	Unchanged
Maze Therapeutics IncMAZE	COM	578784100	47.8	1.4%	1,602,034	Unchanged
Relmada Therapeutics IncRLMD	COM	75955J402	47.4	1.4%	6,844,305	Added+2,000,925
Oric Pharmaceuticals IncORIC	COM	68622P109	46.8	1.4%	4,319,765	Unchanged
Crescent Biopharma Inc.	COM	G2545C104	38.4	1.2%	2,133,576	Unchanged
Zura Bio Ltd	CLASS A ORD SHS	G9TY5A101	38.0	1.2%	6,434,990	Unchanged
Adlai Nortye LtdANL	SPONSORED ADS	00704R109	36.9	1.1%	3,212,731	Unchanged
Enliven Therapeutics IncELVN	COM	29337E102	26.7	0.8%	526,331	Reduced−1,200,000
Cybin Inc	COM NEW	23256X407	25.5	0.8%	3,851,654	Unchanged
Cullinan Therapeutics IncCGEM	COM	230031106	25.1	0.8%	1,379,965	Unchanged
Century Therapeutics IncIPSC	COM	15673T100	21.3	0.6%	8,695,652	Unchanged
Artiva Biotherapeutics IncARTV	COM	04317A107	19.8	0.6%	2,043,596	Added+434,027
Cytomx Therapeutics IncCTMX	COM	23284F105	18.7	0.6%	4,982,124	Reduced−5,000,000
Achieve Life Science IncACHV	COM	004468500	18.0	0.5%	2,751,032	New+2,751,032
Parabilis Medicines IncPBLS	COM	698955101	17.1	0.5%	625,000	New+625,000
Surrozen IncSRZN	COM NEW	86889P208	16.4	0.5%	632,931	Unchanged
Korro Bio IncKRRO	COM	500946108	13.3	0.4%	1,009,500	Unchanged
Alto Neuroscience IncANRO	COM SHS	02157Q109	13.2	0.4%	500,000	Unchanged
X4 Pharmaceuticals IncXFOR	COM NEW	98420X202	9.0	0.3%	1,934,253	Added+1,603,728
Research Alliance Corp III	ORD SHS CL A	G75226103	3.2	<0.1%	300,000	New+300,000
Inmed Pharmaceuticals IncINM	COM NEW	457637700	0.1	<0.1%	32,685	New+32,685

Sold out: 4 positions

Held at the end of the quarter before and not reported this quarter.

Venrock Adviser, LLC, positions sold out
Issuer	Class	CUSIP	Weight	Change on the quarter before
Engene Holdings Inc	COM	29286M105	0.0%	Sold out−4,771,414
Kalvista Pharmaceuticals Inc	COM	483497103	0.0%	Sold out−6,474,485
Septerna IncSEPN	COM	81734D104	0.0%	Sold out−506,056
Tenax Therapeutics IncTENX	COM NEW	88032L605	0.0%	Sold out−1,675,262

Source: SEC EDGAR, Form 13F-HR, accession 0001615982-26-000015 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.